Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur Therapie der chorioidalen Neovaskularisation bei Myopie (Stand: März 2014)

Die Stellungnahme fasst die derzeitigen Empfehlungen zur Therapie chorioidaler Neovaskularisationen bei Myopie zusammen. Grundlage ist eine Literaturrecherche, angelehnt an das „Manual Systematische Literaturrecherche für die Erstellung von Leitlinien, Version 1.0“ [14]. Bei der Diagnostik wird auf die aktuelle Stellungnahme „Die Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration: Therapeutische Strategien“ (Ophthalmologe und Klin. Monatsblätter Febr. 2013) verwiesen ([10]; http://cms.augeninfo.de/fileadmin/stellungnahmen/Anti-VEGF-Therapie_bei_der_neovask_Therapeut_Strategie.pdf).

• Literatur

• 1 Wolf S, Balciuniene VJ, Laganovska G et al. RADIANCE Study Group. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014; 121: 682-692
• 2 Baba T, Kubota-Taniai M, Kitahashi M et al. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 2010; 94: 864-870
• 3 Bandello F. Twelve-month efficacy and safety of ranibizumab 0.5 mg(RBZ) versus verteporfin photodynamic therapy(vPDT) in the treatment of visual impairment(VI) due to choroidal neovascularization(CNV) secondary to pathologic myopia (PM). ARVO Abstract 2013; Program #1247.
• 4 Bandello F, Parodi MB, Iacono P et al. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia. Retina 2013; 33: 593-597
• 5 Bressler NM, Arnold J, Benchaboune M et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion compositionʼs impact on vision outcomes-TAP report No. 3. Arch Ophthalmol 2002; 120: 1443-1454
• 6 Chan A, Blumenkranz MS, Wu KH et al. Photodynamic therapy with and without adjunctive intravitreal triamcinolone acetonide: a retrospective comparative study. Ophthalmic Surg Lasers Imaging 2009; 40: 561-569
• 7 Chang L, Pan CW, Ohno-Matsui K et al. Myopia-related fundus changes in Singapore adults with high myopia. Am J Ophthalmol 2013; 155: 991-999
• 8 Cohen SY. Anti-VEGF drugs as the 2009 firstline therapy for choroidal neovascularization in pathologic myopia. Retina 2009; 29: 1062-1066
• 9 Cornut PL, Poli M, Feldman A et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month results. J Fr Ophtalmol 2010; 33: 327-333
• 10 DOG, RG, BVA. Die Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration: Therapeutische Strategien. Ophthalmologe 2013; 110: 191-198
• 11 DOG, RG, BVA. Die Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration: Therapeutische Strategien. Klin Monatsbl Augenheilkd 2013; 230: 170-177
• 12 DOG, RG, BVA. Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur Therapie der chorioidalen Neovaskularisation bei Myopie. Ophthalmologe 2010; 107: 494-496
• 13 DOG, RG, BVA. Aktuelle Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands „Neue Aspekte in der Therapie der neovaskulären altersabhängigen Makuladegeneration“. Ophthalmologe 2009; 106: 457-464 und Klin Monatsbl Augenheilkd 2009; 226: 388–395
• 14 Deutsches Cochrane-Zentrum, A.d.W.M.F.-I.f.M.W, Ärztliches Zentrum für Qualität in der Medizin. Manual Systematische Literaturrecherche für die Erstellung von Leitlinien. Im Internet:. http://wwwcochranede/de/webliographie-litsuche Stand: 9.12.2013
• 15 Franqueira N, Cachulo ML, Pires I et al. Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab. Ophthalmologica 2012; 227: 39-44
• 16 Gharbiya M, Allievi F, Conflitti S et al. Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study. Clin Ter 2010; 161: e87-e93
• 17 Gharbiya M, Giustolisi R, Allievi F et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab – a randomized controlled trial. Am J Ophthalmol 2010; 149: 458-464
• 18 Han DP, McAllister JT, Weinberg DV et al. Combined intravitreal anti-VEGF and verteporfin photodynamic therapy for juxtafoveal and extrafoveal choroidal neovascularization as an alternative to laser photocoagulation. Eye (Lond) 2010; 24: 713-716
• 19 Hayashi K, Ohno-Matsui K, Shimada N et al. Long-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic myopia. Am J Ophthalmol 2011; 151: 137-147
• 20 Hayashi K, Ohno-Matsui K, Shimada N et al. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology 2010; 117: 1595-1611
• 21 Iacono P, Parodi MB, Papayannis A et al. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina 2012; 32: 1539-1546
• 22 Konstantinidis L, Mantel I, Pournaras JA et al. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247: 311-318
• 23 Lai TY, Chan WM, Liu DT et al. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009; 29: 750-756
• 24 Maberley D. Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial. Ophthalmology 2009; 116: 2149-2157
• 25 Pan CW, Boey PY, Cheng CY et al. Myopia, axial length, and age-related cataract: the Singapore Malay eye study. Invest Ophthalmol Vis Sci 2013; 54: 4498-4502
• 26 Pan CW, Cheng CY, Saw SM et al. Myopia and age-related cataract: a systematic review and meta-analysis. Am J Ophthalmol 2013; 156: 1021-1033
• 27 Parmeggiani F, Costagliola C, Incorvaia C et al. Pharmacogenetic aspects in therapeutic management of subfoveal choroidal neovascularisation: role of factor XIII-A 185 T-allele. Curr Drug Targets 2011; 12: 138-148
• 28 Parodi MB, Iacono P, Papayannis A et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 2010; 128: 437-442
• 29 Ruiz-Moreno JM, Montero JA, Gomez-Ulla F. Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularisation treated by intravitreal bevacizumab. Br J Ophthalmol 2009; 93: 1693-1694
• 30 Silva RM, Ruiz-Moreno JM, Rosa P et al. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 2010; 30: 407-412
• 31 Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol 2008; 53: 121-138
• 32 Tufail A, Patel PJ, Sivaprasad S et al. Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond) 2013; 27: 786
• 33 Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularisation in pathologic myopia. Cochrane Database Syst Rev 2005; (4) CD004765
• 34 Voykov B, Gelisken F, Inhoffen W et al. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years?. Graefes Arch Clin Exp Ophthalmol 2010; 248: 543-550
• 35 Wang E, Chen Y. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina 2013; 33: 1375-1392